Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab.

Kunert A, Basak EA, Hurkmans DP, Balcioglu HE, Klaver Y, van Brakel M, Oostvogels AAM, Lamers CHJ, Bins S, Koolen SLW, van der Veldt AAM, Sleijfer S, Mathijssen RHJ, Aerts JGJV, Debets R.

J Immunother Cancer. 2019 Jun 8;7(1):149. doi: 10.1186/s40425-019-0608-y.

2.

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.

de Goeje PL, Klaver Y, Kaijen-Lambers MEH, Langerak AW, Vroman H, Kunert A, Lamers CHJ, Aerts JGJV, Debets R, Hendriks RW.

Front Immunol. 2018 Sep 7;9:2034. doi: 10.3389/fimmu.2018.02034. eCollection 2018.

3.

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation.

Duinhouwer LE, Beije N, van der Holt B, Rijken-Schelen A, Lamers CH, Somers J, Braakman E, Cornelissen JJ.

Bone Marrow Transplant. 2018 Jun;53(6):673-682. doi: 10.1038/s41409-018-0103-y. Epub 2018 Feb 9.

PMID:
29426829
4.

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk.

Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R.

Clin Cancer Res. 2017 Oct 15;23(20):6012-6020. doi: 10.1158/1078-0432.CCR-17-1012. Epub 2017 Jun 23. Review.

5.

Graft predominance after double umbilical cord blood transplantation: a review.

Cornelissen JJ, Kalin B, Lamers CHJ.

Stem Cell Investig. 2017 May 26;4:47. doi: 10.21037/sci.2017.05.09. eCollection 2017. Review.

6.

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.

Klaver Y, van Steenbergen SC, Sleijfer S, Debets R, Lamers CH.

Front Immunol. 2016 Dec 26;7:648. doi: 10.3389/fimmu.2016.00648. eCollection 2016.

7.

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation.

Lamers CH, Wijers R, van Bergen CA, Somers JA, Braakman E, Gratama JW, Debets R, Falkenburg JH, Cornelissen JJ.

Blood. 2016 Oct 27;128(17):2165-2174. Epub 2016 Aug 16.

8.

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.

Klaver Y, van Steenbergen SCL, Sleijfer S, Debets R, Lamers CHJ.

Clin Immunol. 2016 Aug;169:107-113. doi: 10.1016/j.clim.2016.06.014. Epub 2016 Jul 1.

PMID:
27377533
9.

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.

Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R.

Biochem Soc Trans. 2016 Jun 15;44(3):951-9. doi: 10.1042/BST20160037.

PMID:
27284065
10.

Adoptive T-cell therapy: a need for standard immune monitoring.

Klaver Y, Kunert A, Sleijfer S, Debets R, Lamers CH.

Immunotherapy. 2015;7(5):513-33. doi: 10.2217/imt.15.23. Review.

PMID:
26065477
11.

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.

Lamers CH, van Steenbergen-Langeveld S, van Brakel M, Groot-van Ruijven CM, van Elzakker PM, van Krimpen B, Sleijfer S, Debets R.

Hum Gene Ther Methods. 2014 Dec;25(6):345-57. doi: 10.1089/hgtb.2014.051.

12.

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors.

van der Biessen DA, Burger H, de Bruijn P, Lamers CH, Naus N, Loferer H, Wiemer EA, Mathijssen RH, de Jonge MJ.

Clin Cancer Res. 2014 Sep 15;20(18):4776-83. doi: 10.1158/1078-0432.CCR-14-0325. Epub 2014 Jul 14.

13.

Genetically modified T lymphocytes: more than just direct effectors.

Lamers CH, Debets R.

Immunotherapy. 2013 Jul;5(7):691-4. doi: 10.2217/imt.13.62.

PMID:
23829619
14.

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW.

Mol Ther. 2013 Apr;21(4):904-12. doi: 10.1038/mt.2013.17. Epub 2013 Feb 19.

15.

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.

Lamers CH, van Elzakker P, van Steenbergen SC, Luider BA, Groot C, van Krimpen BA, Vulto A, Sleijfer S, Debets R, Gratama JW.

Cytotherapy. 2013 May;15(5):620-6. doi: 10.1016/j.jcyt.2012.12.006. Epub 2013 Feb 4.

PMID:
23388583
16.

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study.

de Raaf PJ, Sleijfer S, Lamers CH, Jager A, Gratama JW, van der Rijt CC.

Cancer. 2012 Dec 1;118(23):6005-11. doi: 10.1002/cncr.27613. Epub 2012 Jun 26.

17.

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

de Jongste AH, de Graaf MT, Martinuzzi E, van den Broek PD, Kraan J, Lamers CH, Mallone R, Gratama JW, Sillevis Smitt PA.

Neuro Oncol. 2012 Jul;14(7):841-8. doi: 10.1093/neuonc/nos118. Epub 2012 May 15.

18.

Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.

Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA.

Clin Cancer Res. 2010 Dec 1;16(23):5852-61. doi: 10.1158/1078-0432.CCR-10-1280.

19.

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R, Gratama JW.

Blood. 2011 Jan 6;117(1):72-82. doi: 10.1182/blood-2010-07-294520. Epub 2010 Oct 1.

20.

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells.

Strijbos MH, van Krimpen BA, Debets R, Kraan J, Sleijfer S, Gratama JW, Lamers CH.

Thromb Haemost. 2010 Aug;104(2):318-26. doi: 10.1160/TH09-08-0594. Epub 2010 Jun 29.

PMID:
20589320
21.

Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies.

Strijbos MH, Snijder CA, Kraan J, Lamers CH, Gratama JW, Duvekot JJ.

Cytometry B Clin Cytom. 2010 Nov;78(6):382-6. doi: 10.1002/cyto.b.20537.

22.

Quantification of circulating endothelial cells by flow cytometry.

Strijbos MH, Kraan J, Lamers CH, Sleijfer S, Gratama JW.

Clin Cancer Res. 2009 May 15;15(10):3640; author reply 3640-1. doi: 10.1158/1078-0432.CCR-09-0160. No abstract available.

23.

No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes.

de Beukelaar JW, Milikan JC, Verjans GM, de Graaf MT, van Norden Y, Lamers CH, van den Bent MJ, Bromberg JE, Hulsenboom E, Sintnicolaas K, Gratama JW, Sillevis Smitt PA.

J Neurol. 2009 Feb;256(2):279-82. doi: 10.1007/s00415-009-0051-y. Epub 2009 Feb 27. No abstract available.

PMID:
19252764
24.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, Ter Steeg J, Brandely M, Puozzo Ch, Verweij J.

Eur J Cancer. 2009 Jul;45(10):1764-72. doi: 10.1016/j.ejca.2009.01.026. Epub 2009 Feb 27.

PMID:
19251409
25.

Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.

Lamers CH, Willemsen RA, van Elzakker PM, Gratama JW, Debets R.

J Immunother. 2009 Apr;32(3):272-9. doi: 10.1097/CJI.0b013e318199840a.

PMID:
19242373
26.

Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage.

Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, Terstappen LW, Gratama JW.

Thromb Haemost. 2008 Oct;100(4):642-7.

PMID:
18841287
27.

Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield.

Lamers CH, van Elzakker P, van Steenbergen SC, Sleijfer S, Debets R, Gratama JW.

Cytotherapy. 2008;10(4):406-16. doi: 10.1080/14653240801982961.

PMID:
18574773
28.

Circulating endothelial cells in oncology: pitfalls and promises.

Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S.

Br J Cancer. 2008 Jun 3;98(11):1731-5. doi: 10.1038/sj.bjc.6604383. Epub 2008 May 27. Review.

29.

Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis.

Mondria T, Lamers CH, te Boekhorst PA, Gratama JW, Hintzen RQ.

J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1013-5. doi: 10.1136/jnnp.2007.133520. Epub 2008 Jan 25.

PMID:
18223013
30.

Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.

Lamers CH, van Elzakker P, Luider BA, van Steenbergen SC, Sleijfer S, Debets R, Gratama JW.

Cancer Gene Ther. 2008 Apr;15(4):268-74. doi: 10.1038/sj.cgt.7701114. Epub 2008 Jan 18.

PMID:
18202714
31.

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.

Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW.

Cancer Immunol Immunother. 2007 Dec;56(12):1875-83. Epub 2007 May 4.

PMID:
17479266
33.

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.

J Clin Oncol. 2006 May 1;24(13):e20-2. No abstract available.

PMID:
16648493
34.

T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants.

Te Boekhorst PA, Lamers CH, Schipperus MR, Hintzen RQ, van der Holt B, Cornelissen JJ, Löwenberg B, Gratama JW.

Bone Marrow Transplant. 2006 Apr;37(8):763-72.

PMID:
16518423
35.
36.

Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.

Lamers CH, Willemsen RA, van Elzakker P, van Krimpen BA, Gratama JW, Debets R.

Cancer Gene Ther. 2006 May;13(5):503-9.

PMID:
16282986
37.

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.

Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Gratama JW, Stoter G, Huber C, Hack CE.

Cancer Immunol Immunother. 2005 Jan;54(1):37-43.

PMID:
15693137
38.

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):134-40. Review.

PMID:
15471217
39.

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M.

J Immunother. 2004 Mar-Apr;27(2):124-35.

PMID:
14770084
40.
41.

Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.

Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, Lamers CH, Masclee AA.

Gut. 2003 Jan;52(1):109-15.

42.

Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.

Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL.

Cancer Gene Ther. 2002 Jul;9(7):613-23.

43.

Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies.

van den Bent MJ, Lamers CH, van 't Veer MB, Sillevis Smitt PA, Bolhuis RL, Gratama JW.

Ann Hematol. 2002 Apr;81(4):187-91. Epub 2002 Mar 26.

PMID:
11976819
44.
45.

Interleukin 12 induces activation of fibrinolysis and coagulation in humans.

Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Bolhuis RL, Stoter G, Huber C, Hack C.

Br J Haematol. 2001 Feb;112(2):499-505.

PMID:
11167854
46.

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE.

Clin Cancer Res. 1999 Dec;5(12):3983-9.

47.

Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures.

Lamers CH, Gratama JW, Luider-Vrieling B, Bolhuis RL, Bast EJ.

J Immunother. 1999 Jul;22(4):299-307.

PMID:
10404431
48.

Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients.

Bolhuis RL, Willemsen RA, Lamers CH, Stam K, Gratama JW, Weijtens ME.

Adv Exp Med Biol. 1998;451:547-55. No abstract available.

PMID:
10026926
49.

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.

de Wit R, Kruit WH, Lamers CH, van 't Veer MB, Luyten AA, van Beurden V, Harteveld M, Planting AS, Schmitz PI, Stoter G, Bolhuis RL, Verweij J.

Br J Cancer. 1998 Jun;77(12):2363-6.

50.

Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.

Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR Jr, Coney LR.

J Immunother. 1997 Nov;20(6):496-504.

PMID:
9409456

Supplemental Content

Loading ...
Support Center